Bavarian Nordic Raises Outlook Again After Another U.S. Smallpox, Monkeypox Vaccine Orders

• (PLX AI) - Bavarian Nordic Outlook FY revenue DKK 1,800-2,000 million, up from DKK 1,400-1,600 million.
• • Outlook FY EBITDA DKK -900 to -700 million, up from DKK -1,100 to -900 million
• • Bavarian Nordic Receives an Additional Order for JYNNEOS Smallpox and Monkeypox Vaccine from the U.S. Government
• • With the previous order from BARDA for 1.4 million doses of liquid-frozen JYNNEOS, awarded in 2020, this order will bring the total U.S. inventory of the vaccine to nearly 2 million doses